How two companies sprinted ahead in the extraordinary race for a COVID vaccine

  • 📰 smh
  • ⏱ Reading Time:
  • 54 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 25%
  • Publisher: 80%

ประเทศไทย ข่าว ข่าว

ประเทศไทย ข่าวล่าสุด,ประเทศไทย หัวข้อข่าว

Just as the novel coronavirus was gaining a foothold in the United States in mid-March, Pfizer chief executive Albert Bourla called on his top vaccine scientists and laid out a clear mission

Add articles to your saved list and come back to them any time.:

"He did not want us to focus on the potential barriers we might face, but instead said that it is much better to try to do something that seemed impossible, and even if you don't succeed, you still have done something great, " said Dormitzer, noting that new vaccine development can cost on the order of $US1 billion .What followed was a full-bore effort carried out under strict coronavirus lockdown conditions, .

In Pfizer's and BioNTech's case, decision-making that normally would take months was reduced to days, including the crucial call on which vaccine version to use in a human clinical trial that has enrolled about 44,000 people worldwide so far. At Novartis AG, Dormitzer began testing novel ways to make vaccines using messenger ribonucleic acid, or mRNA, which contains instructions for human cells. In this case, scientists introduce mRNA instructions for cells to make a portion of a virus, which the immune system recognises as a threat and counters with a protective response. No actual virus is involved in the process.

 

ขอบคุณสำหรับความคิดเห็นของคุณ ความคิดเห็นของคุณจะถูกเผยแพร่หลังจากได้รับการตรวจสอบแล้ว

understand coronavirus vaccine and the three vaccine candidates now. Coronavirus Vaccines Candidates works only under these conditions.

WE DO NOT NEED A DAMN VIRUS, THERE IS NOTHING NEW TO VAX AGAINST, THE WESTERN MEDIA ARE DANGEROUS PROPAGANDISTS FOR BIG PHARMA

เราได้สรุปข่าวนี้มาให้อ่านอย่างรวดเร็ว หากสนใจข่าว สามารถอ่านฉบับเต็มได้ที่นี่ อ่านเพิ่มเติม:

 /  🏆 6. in TH

ประเทศไทย ข่าวล่าสุด, ประเทศไทย หัวข้อข่าว